Wednesday, August 5, 2009

Oncothyreon Gets $15M in PIPE

Seattle-based Oncothyreon, a publicly held biotech firm developing treatments for cancer, has scored $15M in a private placement in the publicly held firm. According to Oncothyreon, it is seeling 2.28 million shares of its common stock and warrants to purchase 684,000 shares of its stock for approximately $15.0M. The firm did not detail the investors associated with the deal. The placement agent for the funding effort was Rodman Renshaw, with Boenning Scattergood acting as a financial advisor in the offering.